Status:
RECRUITING
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
Lead Sponsor:
Institut fuer Frauengesundheit
Collaborating Sponsors:
AGO Breast Study Group e.V.
Novartis Pharmaceuticals
Conditions:
Breast Cancer
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Detailed Description
This is a prospective, multicenter, phase IV, one-arm, open-label clinical trial investigating patients treated with ribociclib and standard of care endocrine therapy for hormone receptor positive (HR...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
October 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05452213
Start Date
October 12 2022
End Date
October 1 2026
Last Update
April 18 2023
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gynecology and Obstetrics, Erlangen University Hospital
Erlangen, Bavaria, Germany, 91054
2
Department of Gynecology and Obstetrics, University Medicine Mainz
Mainz, Hesse, Germany, 55131
3
Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH
Bottrop, North Rhine-Westphalia, Germany, 46236
4
Klinikum St Marien Amberg
Amberg, Germany, 92224